MUMBAI, India, Feb. 13 -- Intellectual Property India has published a patent application (202641008792 A) filed by Dr. S. Khaleel Basha; Mr. M. Syed Muzammil; Mr. R. Dhandayuthabani; Dr. J. Annie Kamala Florence; Dr. V. Sugantha Kumari; Dr. P. Narmatha Christy; and Dr. T. Nalini, Melvisharam, Tamil Nadu, on Jan. 28, for 'hybrid nanolipid-polymer nanoparticles for oral delivery of insulin.'
Inventor(s) include Dr. S. Khaleel Basha; Mr. M. Syed Muzammil; Mr. R. Dhandayuthabani; Dr. J. Annie Kamala Florence; Dr. V. Sugantha Kumari; Dr. P. Narmatha Christy; and Dr. T. Nalini.
The application for the patent was published on Feb. 13, under issue no. 07/2026.
According to the abstract released by the Intellectual Property India: "The present invention discloses a cost-effective hybrid nanolipid-polymer nanoparticle system for the oral delivery of insulin intended for diabetes management. Insulin is initially dissolved in a physiological buffer and converted into a hydrophobic ion pair using bile salt counter-ions to enhance lipophilicity and stability. The ion-paired insulin is encapsulated within a nanostructured lipid carrier composed of glyceryl monostearate and medium-chain triglyceride oil, stabilized by polysorbate-based surfactants. The lipid nanoparticles are subsequently coated with a pH-responsive polymeric shell comprising pectin and poly(vinyl alcohol) using a water-in-oil-in-water multiple emulsion technique followed by ionic cross-linking. The resulting multilayered hybrid nanoparticles protect insulin from gastric acidity and enzymatic degradation, enable controlled intestinal release, and enhance epithelial permeability. The formulation significantly improves intestinal stability and oral bioavailability of insulin, providing a safe, non-invasive alternative to injectable insulin therapy and improving patient compliance in long-term diabetes treatment."
Disclaimer: Curated by HT Syndication.
